Cervicovaginal microflora and pregnancy outcome: results of a double-blind, placebo-controlled trial of erythromycin treatment

Am J Obstet Gynecol. 1990 Nov;163(5 Pt 1):1580-91. doi: 10.1016/0002-9378(90)90632-h.


Available information suggests that some instances of preterm birth or premature rupture of membranes are associated with clinically unrecognized infection and inflammation of the lower uterine segment, decidua, and fetal membranes. Various cervicovaginal microorganisms have been recovered from these sites. Many of these microorganisms produce factors that may lead to weakening of the fetal membranes, release of prostaglandins, or both. This study evaluated the presence of various lower genital tract microflora and bacterial conditions in 229 women enrolled in a double-blind, placebo-controlled trial of short-course erythromycin treatment at 26 to 30 weeks' gestation to prevent preterm birth. Demographic, obstetric, and microbiologic parameters were prospectively evaluated. Premature rupture of membranes occurred less frequently (p less than 0.01) among women who received erythromycin (6%) versus placebo (16%). Preterm premature rupture of membranes also occurred less frequently, although not significantly (p = 0.3) in patients who received erythromycin (2%) versus placebo (5%). Erythromycin treatment significantly decreased the occurrence of premature rupture of membranes among women who were initially positive for Chlamydia trachomatis infection. Logistic regression analysis demonstrated that C. trachomatis (p = 0.05; odds ratio, 9), vaginal wash phospholipase C (p = 0.08; odds ratio, 6) and prior preterm birth (p = 0.007; odds ratio 17) were associated with increased risk of preterm birth. Bacterial vaginosis, Mycoplasma hominis, Ureaplasma urealyticum were not significantly associated with increased risk of preterm birth or preterm rupture of membranes. These findings support a role for selected lower genital tract microflora in preterm birth and premature rupture. Large controlled treatment trials of specific infections or conditions associated with preterm birth and premature rupture of membranes are required to confirm the value of antimicrobial treatments in prevention of microbial-associated preterm birth.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Bacterial Infections / complications
  • Bacterial Infections / drug therapy
  • Bacterial Infections / microbiology
  • Cervix Uteri / microbiology*
  • Double-Blind Method
  • Erythromycin / therapeutic use*
  • Female
  • Fetal Membranes, Premature Rupture / etiology
  • Fetal Membranes, Premature Rupture / microbiology
  • Fetal Membranes, Premature Rupture / prevention & control
  • Follow-Up Studies
  • Genital Diseases, Female / complications
  • Genital Diseases, Female / drug therapy
  • Genital Diseases, Female / microbiology
  • Humans
  • Multivariate Analysis
  • Obstetric Labor, Premature / etiology
  • Obstetric Labor, Premature / microbiology
  • Obstetric Labor, Premature / prevention & control
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy
  • Pregnancy Complications, Infectious / microbiology
  • Pregnancy Outcome*
  • Prospective Studies
  • Regression Analysis
  • Risk Factors
  • Vagina / microbiology*


  • Erythromycin